This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Petzold, A Articles by Clanet, M. Search for Related Content PubMed PubMed Citation Articles by Petzold, A Articles by Clanet, M. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis

Institute of Neurology, Department of Neuroimmunology, Queen Square, London WC1N 3BG, UK, a.petzold{at}ion.ucl.ac.uk

D Brassat

Department of Neurology, Centre Hospitalier Purpan, Toulouse, France

P Mas

Department of Neurology, Centre Hospitalier Purpan, Toulouse, France

K Rejdak

Institute of Neurology, Department of Neuroimmunology, Queen Square, London WC1N 3BG, UK, Department of Neurology, Medical University, Lublin, Poland

G Keir

Institute of Neurology, Department of Neuroimmunology, Queen Square, London WC1N 3BG, UK

G Giovannoni

Institute of Neurology, Department of Neuroimmunology, Queen Square, London WC1N 3BG, UK

E J Thompson

M. Clanet

Department of Neurology, Centre Hospitalier Purpan, Toulouse, France

Background: This study aimed to investigate if treatment response could retrospectively be related to inflammatory or axonal patho logy as measured by plasma surrogate markers. Methods: In this 1-year observational study 30 multiple sclerosis (MS) patients with relapsing-remitting disease were treated with intramuscular IFNb-1a or subcutaneous IFNb-1b. Responders and nonresponders were defined according to clinical and magnetic resonance imaging criteria. The control group consisted of 14 healthy subjects. Plasma levels of surrogate markers for inflammation (nitric oxide metabolites (NO x)), astrocytic activation (S100B) and axonal damage (NfH^SMI35) were measured using standard assays. Results: There were 11 nonresponders and 19 responders to IFNb treatment. Median S100B levels were elevated in a higher proportion of treatment responders (63%, 42.9 pg/mL) compared to nonresponders (18%, 11.7 pg/mL, PB- 0.05, Fisher’s exact test) and controls (0%, 2 pg/mL, PB- 0.001). Levels of NO x were found to be more frequently elevated in nonresponders (72%, 39 mM) compared to healthy controls (0%, 37 mM, PB- 0.05). Levels of NfH^SMI35 were more frequently elevated in responders (58%, 300 pg/mL, PB- 0.001) and nonresponders (72%, 500 pg/mL, PB- 0.001) compared to controls (0%, 4.5 pg/mL). Conclusion: Patients with relapsing-remitting MS who had surrogate marker supported evidence for astrocytic activation responded more frequently to treatment with IFNb.

Key Words: multiple sclerosis • neurofilament • NfHSMI35 • NOx • S100B • surrogate marker • treatment response

Multiple Sclerosis, Vol. 10, No. 3, 281-283 (2004)
DOI: 10.1191/1352458504ms1021sr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Wiesemann, M. Deb, C. Trebst, B. Hemmer, M. Stangel, and A. Windhagen Effects of interferon-{beta} on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-{beta} treatment in patients with multiple sclerosis Multiple Sclerosis, March 1, 2008; 14(2): 166 - 176. [Abstract] [PDF]

				G S M Ramsaransing, M R Fokkema, A Teelken, A V Arutjunyan, M Koch, and J De Keyser Plasma homocysteine levels in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 189 - 192. [Abstract] [Full Text] [PDF]